CD19 and common variable immunodeficiency: Similarly, our CVID patient B-cells showed faster degradation of specifically BCR-targeted DQ-BSA in comparison to non-targeted DQ-BSA or CD19+ B-cells derived from healthy individuals (Figure 3F).